227 related articles for article (PubMed ID: 34961307)
1. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
[TBL] [Abstract][Full Text] [Related]
2. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
3. In situ conversion of rose bengal microbubbles into nanoparticles for ultrasound imaging guided sonodynamic therapy with enhanced antitumor efficacy.
Hou R; Liang X; Li X; Zhang X; Ma X; Wang F
Biomater Sci; 2020 May; 8(9):2526-2536. PubMed ID: 32215400
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.
Song KH; Trudeau T; Kar A; Borden MA; Gutierrez-Hartmann A
Nanotheranostics; 2019; 3(2):212-222. PubMed ID: 31183315
[TBL] [Abstract][Full Text] [Related]
5. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
6. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
7. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
[TBL] [Abstract][Full Text] [Related]
8. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D
Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
11. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
[TBL] [Abstract][Full Text] [Related]
12. Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine.
Hu N; Yin JF; Ji Z; Hong Y; Wu P; Bian B; Song Z; Li R; Liu Q; Wu F
Cell Physiol Biochem; 2017; 44(6):2158-2173. PubMed ID: 29241186
[TBL] [Abstract][Full Text] [Related]
13. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
[TBL] [Abstract][Full Text] [Related]
14. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
Li HK; Morokoshi Y; Nagatsu K; Kamada T; Hasegawa S
Cancer Sci; 2017 Aug; 108(8):1648-1656. PubMed ID: 28514062
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
[TBL] [Abstract][Full Text] [Related]
17. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
18. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
20. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives.
Palle J; Rochand A; Pernot S; Gallois C; Taïeb J; Zaanan A
Drugs; 2020 Mar; 80(4):401-415. PubMed ID: 32077003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
